四川省药品监督管理局奋力书写“十四五”药品安全答卷 固本强基守底线 改革创新追高线

Core Viewpoint - The Sichuan Provincial Drug Administration is actively enhancing drug regulation and quality control through a multi-faceted approach, focusing on safety, efficiency, and public welfare during the "14th Five-Year Plan" period [3][4][9]. Group 1: Regulatory Framework - The Sichuan Provincial Drug Administration is building a scientific and efficient drug regulatory system, emphasizing government leadership, departmental collaboration, and social governance [4]. - A clear responsibility system has been established to enhance regulatory effectiveness, with a three-tier and five-region regulatory framework [4]. - The administration has strengthened coordination with 26 departments to advance drug safety collectively [4]. Group 2: Digital Transformation - Digital transformation initiatives have made drug regulation smarter, with online processing for all regulatory procedures and an electronic traceability system for drugs [5]. - The implementation of a unique identification system for medical devices has resulted in over 22,600 data uploads, ranking eighth nationally [5]. - The establishment of seven key laboratories has positioned Sichuan as a leader in the western region for drug monitoring and safety [5]. Group 3: Talent Development - The administration has developed a professional title evaluation system for pharmaceutical engineering and non-clinical pharmacy, assessing 199 individuals to support high-quality industry development [6]. - Continuous training programs have been conducted, with over 10,000 participants, to enhance the professional skills of regulatory personnel [6]. - Competitions and events have been organized to showcase the capabilities of the drug inspection industry in Sichuan [6]. Group 4: Comprehensive Safety Control - A systematic approach has been adopted to ensure safety throughout the entire drug lifecycle, from research and development to usage [7]. - The administration has conducted over 60,000 inspections in the past five years, achieving a compliance rate of 99.6% for drugs and 98.2% for medical devices [8]. - Collaborative efforts with Chongqing have been initiated to create an integrated drug regulatory model, enhancing regional cooperation [8]. Group 5: Industry Support and Innovation - The Sichuan Provincial Drug Administration is addressing barriers to innovation in the pharmaceutical industry by launching a user community platform for medical devices [9]. - A proactive service model has been implemented to support enterprises, reducing the average review time for innovative products by 86% [10]. - The administration has streamlined approval processes, significantly improving efficiency in drug and medical device registrations [11].